Links that seem to support Remune (all from Yahoo posters):
abstract about 68 patient Remune study:
trinitycorp.com
Agouron link:
agouron.com
XIII International AIDS 2000 - Durban, South Africa
9-14 July 2000:
aids2000.com
Aids conference abstract follows:
XIII International AIDS Conference (AIDS Congrex 2000)July 9-14, 2000
Intl. Convention Ctr., Durban, South Africa
A Double-Blind, Adjuvant-Controlled Trial of HIV-1 Immunogen (Remune„) Mono Therapy in
Asymptomatic, HIV-1 Infected Thai Subjects with CD4 Cell Counts > 300 ul/mm
3Churdboonchart, V.1, Sakondhavat, C.2, Kulpradist, S.3, Isarangkura NaAyudthya, B.
4, Chandeying,V.5, Rugpao, S.6, Boonshuyar, C.
7,Sukeepaisaencharoen, W.7, Sirawaraporn, .1
, Carlo, D.J. andand Moss, R.
1Mahidol University, Bangkok, Thailand2Khon Kaen University Hospital, Khon Kaen, Thailand
3Vajira Hospital, Bangkok, Thailand
4Pramongkut College of Medicine, Songkla University, Songkla, Thailand6
Chiang Mai University, Chiang Mai, Thailand
7Dept. of Biostatistics, Mahidol University, Bangkok, Thailand8
The Immune Response Corporation, California, USA
Background: The study was conducted to examine the effect of HIV-1 Immunogen (Remune),
an HIV specific immune-based therapy in Thailand where the predominant subtype of HIV
infection is subtype E and where access to antiviral drug therapy is limited.
Methods: A 40-week trial was conducted in 297 asymptomatic, HIV infected Thai subjects with
CD4 cell counts greater than 300 ul/mm
3
and not taking antiviral drug therapy. Subjects were
randomized to receive either HIV-1 Immunogen (REMUNE, inactivated gp120-depleted HIV-1 in
incomplete Freund?s adjuvant) or adjuvant control at 0, 12, 24, and 36 weeks at five different
clinical sites in Thailand.
Results: There was a significant difference in changes in CD4 cell counts favoring the HIV-1
Immunogen treated group compared to the adjuvant control (p<0.05). On average, HIV-1
Immunogen treated subjects increased their CD4 cell counts by 84 cells compared to an increase in
38 cells in the control group by week 40. This increase in CD4 cells was associated with increased
HIV specific immunogenicity as shown by Western blots and enhanced HIV-1 DTH .
Conclusion: The results of this trial indicate that the HIV-1 Immunogen is safe and significantly
increases CD4 cell counts and HIV specific immunity compared to the adjuvant control group.
This study also suggests that this therapy may be an important treatment alternative in countries
where access to antiviral drugs is limited. |
